chemotherapy use in early-stage breast cancer . J Oncol Pract 2013 ; 9 : 182 – 187 . 2. Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000
Search Results
The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias, and Peter Kabos
Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary
surgical recovery, the patient did not receive adjuvant therapy. Three months after surgery, the patient's CA 19-9 level was elevated at 56.3 U/mL; however, no evidence of recurrence was identified on CT Figure 1. Comprehensive genomic profiling
Merkel Cell Carcinoma: A Population Analysis on Survival
Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld
diagnosed between 2006 to 2012, SLNB was associated with improved DSS on univariate (HR, 0.8; 95% CI, 0.66–0.97; P =.02) but not multivariate analysis. It is possible that patients who had a positive SLNB were selected for further adjuvant therapy and thus
Multimodality Therapy of Localized Gastric Adenocarcinoma
Brian Badgwell
, surgical techniques and incorporation of adjuvant therapy between Eastern and Western clinical trial populations Summarize the need for a broad multidisciplinary approach to the management of patients with gastric cancer Multidisciplinary
Sentinel Lymph Node Mapping for Endometrial Cancer: A Modern Approach to Surgical Staging
Nadeem R. Abu-Rustum
the actual extent of disease rather than on perceived risks based on uterine factors, such as grade, histology, and depth of myometrial invasion, which helps tailor adjuvant therapy. 14 Unfortunately, many patients with early-stage endometrial cancer
Integrating Immunotherapy Into the Management of Renal Cell Carcinoma
Matthew Zibelman and Elizabeth R. Plimack
shown to dramatically diminish in patients with RCC after nephrectomy, which, for adjuvant therapy, would mean essentially losing the target before firing the first shot. 19 Treating patients preoperatively or perioperatively (ie, both before and after
Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer
Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson, and Yi-Jen Chen
definitive resection for gastric adenocarcinoma and impact of adjuvant therapies . Int J Radiat Oncol 2017 ; 98 : 1106 – 1115 . 29. Datta J McMillan MT Ecker BL . Implications of lymph node staging on selection of adjuvant therapy for gastric
Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors
Christina Teng, Venkatesha, Prunella L. Blinman, and Janette L. Vardy
cohort, 29 (23%) patients were planned to receive 3 months of adjuvant therapy, and the remainder (n=97; 77%) were to receive 6 months. Mean “numbness and tingling” reported by patients planned for 3 and 6 months of chemotherapy was 2.7 versus 3
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
) or at recurrence, which occurred at least 1 year from the completion of adjuvant therapy (not reached; n=21; P =.84). Similarly, no difference in mPFS was observed among the 50 patients who received palbociclib as second-line treatment, in the
Associations Between Patient Experience With Care, Race and Ethnicity, and Receipt of CRC Treatment Among SEER-CAHPS Patients With Multiple Comorbidities
Stephanie Navarro, Jennifer Tsui, Afsaneh Barzi, Mariana C. Stern, Trevor Pickering, and Albert J. Farias
patterns of treatment within general stage groupings (stage I, II, or III) for colon and rectal cancer, including care received from the time of surgical resection (as the most important component of curative treatment of CRC) to receipt of adjuvant therapy
